Cephalon Faces Class Cert. Bid In Actiq Marketing Row

Law360, New York (October 30, 2012, 8:25 PM EDT) -- Two companies that chip in for employees' prescription drugs sought class certification last week in a Pennsylvania suit against Cephalon over off-label marketing for the painkiller Actiq, saying the fact that potentially hundreds of companies had to pay for workers' prescriptions made the case suitable for class treatment.

The Indiana Carpenters Welfare Fund and the Pennsylvania Turnpike Commission are seeking $698.9 million – the profits they claim Cephalon made from illegally marketing Actiq, an opiate-based lollipop approved solely for breakthrough cancer pain, to other pain sufferers,...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

EMPLOYERS MUTUAL CASUALTY COMPANY et al v. CEPHALON, INC.


Case Number

2:07-cv-04492

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Other Statutory Actions

Judge

PETRESE B. TUCKER

Date Filed

October 25, 2007

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.